Acute effects of ghrelin administration on glucose and lipid metabolism.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Acute effects of ghrelin administration on glucose and lipid metabolism. / Vestergaard, Esben Thyssen; Djurhuus, Christian Born; Gjedsted, Jakob; Nielsen, Søren; Møller, Niels; Holst, Jens Juul; Jørgensen, Jens Otto Lunde; Schmitz, Ole.

I: Journal of Clinical Endocrinology and Metabolism, Bind 93, Nr. 2, 2007, s. 438-444.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Vestergaard, ET, Djurhuus, CB, Gjedsted, J, Nielsen, S, Møller, N, Holst, JJ, Jørgensen, JOL & Schmitz, O 2007, 'Acute effects of ghrelin administration on glucose and lipid metabolism.', Journal of Clinical Endocrinology and Metabolism, bind 93, nr. 2, s. 438-444. https://doi.org/10.1210/jc.2007-2018

APA

Vestergaard, E. T., Djurhuus, C. B., Gjedsted, J., Nielsen, S., Møller, N., Holst, J. J., Jørgensen, J. O. L., & Schmitz, O. (2007). Acute effects of ghrelin administration on glucose and lipid metabolism. Journal of Clinical Endocrinology and Metabolism, 93(2), 438-444. https://doi.org/10.1210/jc.2007-2018

Vancouver

Vestergaard ET, Djurhuus CB, Gjedsted J, Nielsen S, Møller N, Holst JJ o.a. Acute effects of ghrelin administration on glucose and lipid metabolism. Journal of Clinical Endocrinology and Metabolism. 2007;93(2):438-444. https://doi.org/10.1210/jc.2007-2018

Author

Vestergaard, Esben Thyssen ; Djurhuus, Christian Born ; Gjedsted, Jakob ; Nielsen, Søren ; Møller, Niels ; Holst, Jens Juul ; Jørgensen, Jens Otto Lunde ; Schmitz, Ole. / Acute effects of ghrelin administration on glucose and lipid metabolism. I: Journal of Clinical Endocrinology and Metabolism. 2007 ; Bind 93, Nr. 2. s. 438-444.

Bibtex

@article{852a2240ab4f11ddb5e9000ea68e967b,
title = "Acute effects of ghrelin administration on glucose and lipid metabolism.",
abstract = "CONTEXT: Ghrelin infusion increases plasma glucose and nonesterified fatty acids, but it is uncertain whether this is secondary to the concomitant release of GH. OBJECTIVE: Our objective was to study direct effects of ghrelin on substrate metabolism. DESIGN: This was a randomized, single-blind, placebo-controlled two-period crossover study. SETTING: The study was performed in a university clinical research laboratory. PARTICIPANTS: Eight healthy men aged 27.2 +/- 0.9 yr with a body mass index of 23.4 +/- 0.5 kg/m(2) were included in the study. INTERVENTION: Subjects received infusion of ghrelin (5 pmol x kg(-1) x min(-1)) or placebo for 5 h together with a pancreatic clamp (somatostatin 330 microg x h(-1), insulin 0.1 mU x kg(-1) x min(-1), GH 2 ng x kg(-1) x min(-1), and glucagon 0.5 ng.kg(-1) x min(-1)). A hyperinsulinemic (0.6 mU x kg(-1) x min(-1)) euglycemic clamp was performed during the final 2 h of each infusion. RESULTS: Basal and insulin-stimulated glucose disposal decreased with ghrelin [basal: 1.9 +/- 0.1 (ghrelin) vs. 2.3 +/- 0.1 mg x kg(-1) x min(-1), P = 0.03; clamp: 3.9 +/- 0.6 (ghrelin) vs. 6.1 +/- 0.5 mg x kg(-1) x min(-1), P = 0.02], whereas endogenous glucose production was similar. Glucose infusion rate during the clamp was reduced by ghrelin [4.0 +/- 0.7 (ghrelin) vs. 6.9 +/- 0.9 mg.kg(-1) x min(-1); P = 0.007], whereas nonesterified fatty acid flux increased [131 +/- 26 (ghrelin) vs. 69 +/- 5 micromol/min; P = 0.048] in the basal period. Regional lipolysis (skeletal muscle, sc fat) increased insignificantly with ghrelin infusion. Energy expenditure during the clamp decreased after ghrelin infusion [1539 +/- 28 (ghrelin) vs. 1608 +/- 32 kcal/24 h; P = 0.048], but the respiratory quotient did not differ. Minor but significant elevations in serum levels of GH and cortisol were observed after ghrelin infusion. CONCLUSIONS: Administration of exogenous ghrelin causes insulin resistance in muscle and stimulates lipolysis; these effects are likely to be direct, although a small contribution of GH and cortisol cannot be excluded.",
author = "Vestergaard, {Esben Thyssen} and Djurhuus, {Christian Born} and Jakob Gjedsted and S{\o}ren Nielsen and Niels M{\o}ller and Holst, {Jens Juul} and J{\o}rgensen, {Jens Otto Lunde} and Ole Schmitz",
note = "Keywords: Adult; Blood Glucose; Calorimetry, Indirect; Cross-Over Studies; Energy Metabolism; Fatty Acids, Nonesterified; Ghrelin; Glucagon; Glucose; Glucose Clamp Technique; Humans; Hydrocortisone; Lipid Metabolism; Male; Microdialysis; Muscle, Skeletal; Single-Blind Method",
year = "2007",
doi = "10.1210/jc.2007-2018",
language = "English",
volume = "93",
pages = "438--444",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Acute effects of ghrelin administration on glucose and lipid metabolism.

AU - Vestergaard, Esben Thyssen

AU - Djurhuus, Christian Born

AU - Gjedsted, Jakob

AU - Nielsen, Søren

AU - Møller, Niels

AU - Holst, Jens Juul

AU - Jørgensen, Jens Otto Lunde

AU - Schmitz, Ole

N1 - Keywords: Adult; Blood Glucose; Calorimetry, Indirect; Cross-Over Studies; Energy Metabolism; Fatty Acids, Nonesterified; Ghrelin; Glucagon; Glucose; Glucose Clamp Technique; Humans; Hydrocortisone; Lipid Metabolism; Male; Microdialysis; Muscle, Skeletal; Single-Blind Method

PY - 2007

Y1 - 2007

N2 - CONTEXT: Ghrelin infusion increases plasma glucose and nonesterified fatty acids, but it is uncertain whether this is secondary to the concomitant release of GH. OBJECTIVE: Our objective was to study direct effects of ghrelin on substrate metabolism. DESIGN: This was a randomized, single-blind, placebo-controlled two-period crossover study. SETTING: The study was performed in a university clinical research laboratory. PARTICIPANTS: Eight healthy men aged 27.2 +/- 0.9 yr with a body mass index of 23.4 +/- 0.5 kg/m(2) were included in the study. INTERVENTION: Subjects received infusion of ghrelin (5 pmol x kg(-1) x min(-1)) or placebo for 5 h together with a pancreatic clamp (somatostatin 330 microg x h(-1), insulin 0.1 mU x kg(-1) x min(-1), GH 2 ng x kg(-1) x min(-1), and glucagon 0.5 ng.kg(-1) x min(-1)). A hyperinsulinemic (0.6 mU x kg(-1) x min(-1)) euglycemic clamp was performed during the final 2 h of each infusion. RESULTS: Basal and insulin-stimulated glucose disposal decreased with ghrelin [basal: 1.9 +/- 0.1 (ghrelin) vs. 2.3 +/- 0.1 mg x kg(-1) x min(-1), P = 0.03; clamp: 3.9 +/- 0.6 (ghrelin) vs. 6.1 +/- 0.5 mg x kg(-1) x min(-1), P = 0.02], whereas endogenous glucose production was similar. Glucose infusion rate during the clamp was reduced by ghrelin [4.0 +/- 0.7 (ghrelin) vs. 6.9 +/- 0.9 mg.kg(-1) x min(-1); P = 0.007], whereas nonesterified fatty acid flux increased [131 +/- 26 (ghrelin) vs. 69 +/- 5 micromol/min; P = 0.048] in the basal period. Regional lipolysis (skeletal muscle, sc fat) increased insignificantly with ghrelin infusion. Energy expenditure during the clamp decreased after ghrelin infusion [1539 +/- 28 (ghrelin) vs. 1608 +/- 32 kcal/24 h; P = 0.048], but the respiratory quotient did not differ. Minor but significant elevations in serum levels of GH and cortisol were observed after ghrelin infusion. CONCLUSIONS: Administration of exogenous ghrelin causes insulin resistance in muscle and stimulates lipolysis; these effects are likely to be direct, although a small contribution of GH and cortisol cannot be excluded.

AB - CONTEXT: Ghrelin infusion increases plasma glucose and nonesterified fatty acids, but it is uncertain whether this is secondary to the concomitant release of GH. OBJECTIVE: Our objective was to study direct effects of ghrelin on substrate metabolism. DESIGN: This was a randomized, single-blind, placebo-controlled two-period crossover study. SETTING: The study was performed in a university clinical research laboratory. PARTICIPANTS: Eight healthy men aged 27.2 +/- 0.9 yr with a body mass index of 23.4 +/- 0.5 kg/m(2) were included in the study. INTERVENTION: Subjects received infusion of ghrelin (5 pmol x kg(-1) x min(-1)) or placebo for 5 h together with a pancreatic clamp (somatostatin 330 microg x h(-1), insulin 0.1 mU x kg(-1) x min(-1), GH 2 ng x kg(-1) x min(-1), and glucagon 0.5 ng.kg(-1) x min(-1)). A hyperinsulinemic (0.6 mU x kg(-1) x min(-1)) euglycemic clamp was performed during the final 2 h of each infusion. RESULTS: Basal and insulin-stimulated glucose disposal decreased with ghrelin [basal: 1.9 +/- 0.1 (ghrelin) vs. 2.3 +/- 0.1 mg x kg(-1) x min(-1), P = 0.03; clamp: 3.9 +/- 0.6 (ghrelin) vs. 6.1 +/- 0.5 mg x kg(-1) x min(-1), P = 0.02], whereas endogenous glucose production was similar. Glucose infusion rate during the clamp was reduced by ghrelin [4.0 +/- 0.7 (ghrelin) vs. 6.9 +/- 0.9 mg.kg(-1) x min(-1); P = 0.007], whereas nonesterified fatty acid flux increased [131 +/- 26 (ghrelin) vs. 69 +/- 5 micromol/min; P = 0.048] in the basal period. Regional lipolysis (skeletal muscle, sc fat) increased insignificantly with ghrelin infusion. Energy expenditure during the clamp decreased after ghrelin infusion [1539 +/- 28 (ghrelin) vs. 1608 +/- 32 kcal/24 h; P = 0.048], but the respiratory quotient did not differ. Minor but significant elevations in serum levels of GH and cortisol were observed after ghrelin infusion. CONCLUSIONS: Administration of exogenous ghrelin causes insulin resistance in muscle and stimulates lipolysis; these effects are likely to be direct, although a small contribution of GH and cortisol cannot be excluded.

U2 - 10.1210/jc.2007-2018

DO - 10.1210/jc.2007-2018

M3 - Journal article

C2 - 18042651

VL - 93

SP - 438

EP - 444

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -

ID: 8417878